Development, Commercialization and Supply Agreement - Additional Information (Detail)	1 Months Ended								12 Months Ended
	Jan. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Feb. 29, 2020 USD ($)	Jan. 31, 2020 USD ($)	Sep. 30, 2018 USD ($)	Sep. 30, 2017 USD ($)	Mar. 31, 2016 USD ($)	Feb. 28, 2015 USD ($)	Dec. 31, 2021 USD ($) Item	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)
License And Collaboration Agreements [Line Items]
Revenue recognized related to upfront and milestone payments									$ 2,051,000	$ 6,822,000
Licenses revenue									583,187,000	614,060,000	$ 429,755,000
Deferred revenue		$ 18,632,000							16,709,000	18,632,000	20,846,000
Product Revenue, Net
License And Collaboration Agreements [Line Items]
Licenses revenue									$ 580,320,000	607,025,000	$ 427,391,000
Mochida | In-licenses
License And Collaboration Agreements [Line Items]
Milestones payment	$ 1,000,000.0	1,000,000.0		$ 1,000,000.0
Mochida | In-licenses | Research and Development Expense
License And Collaboration Agreements [Line Items]
Upfront payment												$ 2,700,000
Edding | Out-licenses
License And Collaboration Agreements [Line Items]
Non-refundable up-front received								$ 15,000,000.0
Number of indications of the regulatory milestone events relating to the submission and approval | Item									3
Amounts to be received upon achievement of the regulatory milestone events									$ 33,000,000.0
Sales-based milestone event payment									120,000,000.0
Revenue recognized related to upfront and milestone payments									1,100,000	3,000,000.0
Deferred revenue		10,800,000							9,800,000	10,800,000
Edding | Out-licenses | Licensing Revenue
License And Collaboration Agreements [Line Items]
Licenses revenue									7,100,000	6,100,000
Edding | Out-licenses | Maximum
License And Collaboration Agreements [Line Items]
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone									153,000,000.0
Amounts to be received upon achievement of the regulatory milestone events									15,000,000.0
Sales-based milestone event payment									50,000,000.0
Edding | Out-licenses | Minimum
License And Collaboration Agreements [Line Items]
Amounts to be received upon achievement of the regulatory milestone events									2,000,000.0
Sales-based milestone event payment									5,000,000.0
Edding | Out-licenses | Clinical Trial Application
License And Collaboration Agreements [Line Items]
Non-refundable milestone payment received							$ 1,000,000.0
Biologix FZCo | Out-licenses
License And Collaboration Agreements [Line Items]
Revenue recognition period of non-refundable up-front payment							10 years
Biologix FZCo | Out-licenses | Product Revenue, Net
License And Collaboration Agreements [Line Items]
Licenses revenue									1,400,000	500,000
HLS | Out-licenses
License And Collaboration Agreements [Line Items]
Non-refundable up-front received						$ 5,000,000.0
Revenue recognized related to upfront and milestone payments									900,000	3,900,000
Deferred revenue		$ 7,100,000							6,200,000	7,100,000
Non-refundable up-front received period						6 months
Non-refundable milestone payment received			$ 2,500,000	$ 3,800,000	$ 2,500,000	$ 2,500,000
Non-refundable milestone payment received						3,800,000
HLS | Out-licenses | Health Canada
License And Collaboration Agreements [Line Items]
Non-refundable milestone payment received						2,500,000
HLS | Out-licenses | Licensing Revenue
License And Collaboration Agreements [Line Items]
Licenses revenue									7,500,000	6,600,000
HLS | Out-licenses | Product Revenue, Net
License And Collaboration Agreements [Line Items]
Licenses revenue									$ 0	$ 8,500,000
HLS | Out-licenses | Maximum
License And Collaboration Agreements [Line Items]
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone						$ 50,000,000.0